Delving into the Latest Updates on Shandong Langnuo Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

5-HT1A receptor x 5-HT2A receptor x D2 receptor	1

[Translation] A single-center, open-label, randomized, single-dose, crossover bioequivalence study evaluating the test formulation baricitinib tablets (strength: 4 mg) versus the reference formulation baricitinib tablets (Olumiant®, strength: 4 mg) in healthy adult participants in the fasting and fed states

主要目的：研究空腹和餐后状态下单次口服受试制剂巴瑞替尼片（规格：4 mg，生产厂家：山东朗诺制药有限公司）与参比制剂巴瑞替尼片（Olumiant®，规格：4 mg，生产厂家：Lilly S.A.）在健康成年参与者体内的药代动力学，评价空腹和餐后状态下口服两种制剂的生物等效性。次要目的：评估受试制剂巴瑞替尼片（规格：4 mg）和参比制剂巴瑞替尼片（Olumiant®，规格：4 mg）在健康参与者中的安全性。

[Translation]

Primary objective: To study the pharmacokinetics of a single oral dose of the test preparation baricitinib tablets (specification: 4 mg, manufacturer: Shandong Langnuo Pharmaceutical Co., Ltd.) and the reference preparation baricitinib tablets (Olumiant®, specification: 4 mg, manufacturer: Lilly S.A.) in healthy adult participants in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary objective: To evaluate the safety of the test preparation baricitinib tablets (specification: 4 mg) and the reference preparation baricitinib tablets (Olumiant®, specification: 4 mg) in healthy participants.

Start Date11 Jun 2025

Sponsor / Collaborator

Shandong Langnuo Pharmaceutical Co. Ltd.

CTR20251611

/ CompletedNot Applicable

依巴斯汀口崩片在健康受试者中单中心、随机、开放、单剂量空腹和餐后状态下的生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose bioequivalence study of ebastine orodisintegrating tablets in healthy subjects under fasting and fed conditions

主要目的：比较空腹和餐后给药条件下，山东朗诺制药有限公司生产的依巴斯汀口崩片（10mg）与Almirall, S.A.持证的依巴斯汀口崩片（10mg，商品名：Ebastel Flas）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹和餐后给药条件下，山东朗诺制药有限公司生产的依巴斯汀口崩片（10mg）与Almirall, S.A.持证的依巴斯汀口崩片（10mg，商品名：Ebastel Flas）的安全性。

[Translation]

Primary objective: To compare the differences in absorption extent and rate between Ebastine orodisintegrating tablets (10 mg) produced by Shandong Langnuo Pharmaceutical Co., Ltd. and Ebastine orodisintegrating tablets (10 mg, trade name: Ebastel Flas) licensed by Almirall, S.A. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Ebastine orodisintegrating tablets (10 mg) produced by Shandong Langnuo Pharmaceutical Co., Ltd. and Ebastine orodisintegrating tablets (10 mg, trade name: Ebastel Flas) licensed by Almirall, S.A. under fasting and postprandial administration conditions.

Start Date22 May 2025

Sponsor / Collaborator

Shandong Langnuo Pharmaceutical Co. Ltd.

CTR20251602

/ Active, not recruitingNot Applicable

多替诺雷片在健康受试者中单中心、随机、开放、单剂量空腹和餐后状态下的生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose bioequivalence study of dotinoreplast tablets in healthy subjects under fasting and fed conditions

主要目的：比较空腹和餐后给药条件下，山东朗诺制药有限公司生产的多替诺雷片（2mg）与株式会社富士薬品持证的多替诺雷片（2mg，商品名：URECE®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹和餐后给药条件下，山东朗诺制药有限公司生产的多替诺雷片（2mg）与株式会社富士薬品持证的多替诺雷片（2mg，商品名：URECE®）在健康成年人群中的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of Dotinol Tablets (2 mg) produced by Shandong Langnuo Pharmaceutical Co., Ltd. and Dotinol Tablets (2 mg, trade name: URECE®) certified by Fuji Pharmaceutical Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Dotinol Tablets (2 mg) produced by Shandong Langnuo Pharmaceutical Co., Ltd. and Dotinol Tablets (2 mg, trade name: URECE®) certified by Fuji Pharmaceutical Co., Ltd. in healthy adults under fasting and postprandial administration conditions.

Start Date12 May 2025

Sponsor / Collaborator

Shandong Langnuo Pharmaceutical Co. Ltd.

100 Clinical Results associated with Shandong Langnuo Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shandong Langnuo Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Shandong Langnuo Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shandong Langnuo Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data